Selecta is developing targeted Synthetic Vaccine Particles (tSVP™) and targeted tolerogenic Synthetic Vaccine Particles  (t²SVP™)  for a broad range of therapeutic and prophylactic applications.  Medical indications covered in the Selecta pipeline include stimulatory  tSVP™ vaccines for smoking cessation and relapse prevention, malaria, and cancer.  Selecta has initiated three programs for its tolerogenic t²SVP™ immunotherapies covering type 1 diabetes, food allergies, and orphan indications such as protein replacement therapy and hemophilia.